EYPT - ピ―シビダ (EyePoint Pharmaceuticals Inc.) ピ―シビダ

 EYPTのチャート


 EYPTの企業情報

symbol EYPT
会社名 EyePoint Pharmaceuticals Inc (ピ―シビダ)
分野(sector) Capital Goods   資本財(工業製品)
産業(industry) Biotechnology: Laboratory Analytical Instruments  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アイポイント・ファーマシューティカルズ(Eyepoint Pharmaceuticals Inc.)(旧名:pSivida Corp.)は主に慢性眼疾患の治療用の薬物送達製品を開発する。同社は目の裏目の病気の治療のための3つの製品を開発した。後部セグメントブドウ膜炎のためのMedidurは、主要な第III相臨床試験にあるリード製品候補である。糖尿病性黄斑浮腫(DME)のILUVIENは、米国および欧州連合(EU)諸国で販売されている主要ライセンス製品である。また、Retisertを含む。Medidurは、眼の後部に影響を与える慢性非感染性ブドウ膜炎(後部ブドウ膜炎)を治療するように設計される。ILUVIENは、単回注射からDMEの治療を提供する注射可能なマイクロインサートである。Retisertは、後区域ブドウ膜炎の治療を提供するインプラントである。同社の製品開発プログラムは、DurasertとTethadurの2つの技術プラットフォームを利用して、慢性疾患治療薬と生物製剤を提供することに重点を置く。   ピ―シビダは、米国の医薬品会社。目の奥の慢性疾患の治療に焦点を当てた医薬品「Durasert」と「Tethadur」を開発。また、製品候補「Medidur」は、第3相臨床試験段階である。同社の主要製品「ILUVIEN」は、欧州連合(EU)で承認され、米国食品医薬品局(FDA)では承認が保留されている。   EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
本社所在地 480 Pleasant Street Watertown MA 02472 USA
代表者氏名 Goran A. Ando ゴラン・アンドド
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-926-5000
設立年月日 31868
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 44人
url www.eyepointpharma.com
nasdaq_url https://www.nasdaq.com/symbol/eypt
adr_tso
EBITDA EBITDA(百万ドル) -25.12600
終値(lastsale) 3.28
時価総額(marketcap) 244399517.44
時価総額 時価総額(百万ドル) 250.36050
売上高 売上高(百万ドル) 2.96100
企業価値(EV) 企業価値(EV)(百万ドル) 228.89350
当期純利益 当期純利益(百万ドル) -53.17100
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Eyepoint Pharmaceuticals Inc revenues decreased 61% to $3M. Net loss increased from $18.5M to $53.2M. Revenues reflect United States segment decrease of 62% to $2.9M. Higher net loss reflects Research and Development Expense increase of 12% to $14.9M (expense) General and administrative increase of 3% to $10.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.52 to -$1.15.

 EYPTのテクニカル分析


 EYPTのニュース

   Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) Short Interest Up 6.6% in October  2019/11/17 19:26:47 Modern Readers
Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) was the recipient of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 5,640,000 shares, an increase of 6.6% from the September 30th total of 5,290,000 shares. Approximately 8.8% of the shares of the stock are short sold. Based on […]
   Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded to “Hold” at ValuEngine  2019/11/08 06:52:41 Modern Readers
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Friday, ValuEngine reports. Several other equities research analysts have also commented on EYPT. Laidlaw assumed coverage on Eyepoint Pharmaceuticals in a research note on Monday. They set a “buy” rating and a […]
   2 Candidates That Could Be the Next Biotech Rockets  2019/10/18 12:31:40 TheStreet
Omeros Corp. and EyePoint Pharmaceuticals are two small biotech companies that each have promising treatments that could send their shares skyward….OMER
   EyePoint Pharmaceuticals (EYPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release  2019/07/31 14:36:29 Zacks Investment Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Eyepoint Pharmaceuticals (EYPT) Investor Presentation - Slideshow  2019/06/06 19:33:13 Seeking Alpha
The following slide deck was published by EyePoint Pharmaceuticals, Inc. in conjunction with this event.
   Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) Short Interest Up 6.6% in October  2019/11/17 19:26:47 Modern Readers
Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) was the recipient of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 5,640,000 shares, an increase of 6.6% from the September 30th total of 5,290,000 shares. Approximately 8.8% of the shares of the stock are short sold. Based on […]
   Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded to “Hold” at ValuEngine  2019/11/08 06:52:41 Modern Readers
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Friday, ValuEngine reports. Several other equities research analysts have also commented on EYPT. Laidlaw assumed coverage on Eyepoint Pharmaceuticals in a research note on Monday. They set a “buy” rating and a […]
   2 Candidates That Could Be the Next Biotech Rockets  2019/10/18 12:31:40 TheStreet
Omeros Corp. and EyePoint Pharmaceuticals are two small biotech companies that each have promising treatments that could send their shares skyward….OMER
   EyePoint Pharmaceuticals (EYPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release  2019/07/31 14:36:29 Zacks Investment Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Eyepoint Pharmaceuticals (EYPT) Investor Presentation - Slideshow  2019/06/06 19:33:13 Seeking Alpha
The following slide deck was published by EyePoint Pharmaceuticals, Inc. in conjunction with this event.
   EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2019 Results - Earnings Call Transcript  2019-05-08
EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2019 Earnings Conference Call May 8, 2019, 08:30 AM ET Company Participants David Price - CFO Nancy Lurker - President and CEO Conference Call Participants Andrew D'Silva - B. Riley FBR Yi Chen - H.C. Wainwright Presentation O…
   EyePoint Pharma Q1 top line up 122%  2019-05-08
EyePoint Pharmaceuticals ( EYPT ) Q1 results : Revenues: $2M (+122.2%). More news on: EyePoint Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, , Read more …
   EyePoint Pharmaceuticals misses by $0.11, misses on revenue  2019-05-08
EyePoint Pharmaceuticals (NASDAQ: EYPT ): Q1 GAAP EPS of -$0.20 misses by $0.11 . More news on: EyePoint Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ピ―シビダ EYPT EyePoint Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)